[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"plasma-cell-myeloma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:plasma-cell-myeloma":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,42,67,89,114,137,161,185],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100405971","phase-3-testing-the-use-of-combination-therapy-in-adult-patients-with-newly-diagnosed-multiple-myeloma-the-equate-trial-100405971",false,"NCT04566328","Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial","Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation","Inclusion Criteria:\n\n* STEP 0 - Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2 (PS 3 allowed if secondary to pain)\n* STEP 0 - Patient must have newly diagnosed multiple myeloma (MM) by International Myeloma Working Group (IMWG) criteria\n* STEP 0 - Patient must agree to register to the mandatory REVLIMID Risk Evaluation and Mitigation Strategy (RevREMS) program and be willing and able to comply with the requirements of RevREMS\n* STEP 0 - Patient must be able to undergo diagnostic bone marrow aspirate following preregistration.\n\n  * NOTE: Bone marrow aspirate specimen must be submitted to Adaptive Biotechnologies for clonoSEQ Assay\n  * NOTE: Adaptive Biotechnologies will release results to the diagnostic Portal from the Clonality (ID) test within fourteen (14) days of receipt and reconciliation of fresh bone marrow specimen to the submitting institution\n* STEP 1 - Patient must meet all eligibility criteria in STEP 0 with exception of allergy requirement\n* STEP 1 - Institution must have received the Clonality (ID) test results from Adaptive Biotechnologies and dominant sequences were identified\n* STEP 1 - Patient must have standard risk MM as defined by the Revised International Staging System (RISS) stage I or II\n\n  * NOTE: R-ISS stage is based on serum beta2 microglobulin, albumin and lactate dehydrogenase (LDH) levels along with presence of chromosomal abnormalities (CA) detected by interphase fluorescent in situ hybridization (iFISH). Presence of del(17p), t(4;14), and\u002For t(14;16) is considered high risk and absence of these, including any other findings, are standard risk\n  * R-ISS stage\n\n    * Stage I: ISS stage I \\[beta2 macroglobulin \\\u003C 3.5 mg\u002FL, albumin \\> 3.5 g\u002FdL\\] AND standard-risk CA AND normal LDH\n    * Stage II: Not R-ISS stage I or III\n    * Stage III: ISS stage III \\[beta2 macroglobulin \\> 5.5 mg\u002FL\\] AND high-risk CA OR high LDH (\\> upper limit of normal) \\[patients with stage III are ineligible\\]\n* STEP 1 - Patient must have measurable or evaluable disease as defined by having one or more of the following, obtained within 28 days prior to registration:\n\n  * \\>= 1 g\u002FdL monoclonal protein (M-protein) on serum protein electrophoresis\n  * \\>= 200 mg\u002F24 hours of monoclonal protein on a 24-hour urine protein electrophoresis\n  * Involved free light chain \\>= 10 mg\u002FdL or \\>= 100 mg\u002FL AND abnormal serum immunoglobulin kappa to lambda free light chain ratio (\\\u003C 0.26 or \\> 1.65)\n  * Monoclonal bone marrow plasmacytosis \\>= 30% (evaluable disease)\n* STEP 1 - Patients must have a serum protein electrophoresis (SPEP), urine protein electrophoresis (UPEP), and serum free light chain (FLC) assay performed within 28 days prior to registration. In addition, a bone marrow biopsy and\u002For aspirate is required within 28 days if bone marrow is being followed for response\n\n  * NOTE: UPEP (on a 24-hour collection) is required, no substitute method is acceptable. Urine must be followed monthly if the baseline urine M-spike is \\>= 200 mg\u002F24 hr. Please note that if both serum and urine M-components are present, both must be followed in order to evaluate response\n  * NOTE: The serum free light chain test is required to be done if the patient does not have measurable disease in the serum or urine. Measurable disease in the serum is defined as having a serum M-spike \\>= 1 g\u002FdL. Measurable disease in the urine is defined as having a urine M-spike \\>= 200 mg\u002F24 hr\n* STEP 1 - Calculated creatinine clearance \\> 30 mL\u002Fmin (obtained =\\\u003C 14 days prior to Step 1 registration)\n* STEP 1 - Absolute neutrophil count (ANC) \\>= 1000\u002Fmm\\^3 (obtained =\\\u003C 14 days prior to Step 1 registration)\n* STEP 1 - Untransfused platelet count \\>= 75,000\u002Fmm\\^3 (obtained =\\\u003C 14 days prior to Step 1 registration)\n* STEP 1 - Hemoglobin \\>= 8.0 g\u002FdL (obtained =\\\u003C 14 days prior to Step 1 registration)\n* STEP 1 - Total bilirubin =\\\u003C 1.5 x ULN (institutional upper limit of normal) (obtained =\\\u003C 14 days prior to Step 1 registration)\n* STEP 1 - Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =\\\u003C 3 x ULN (obtained =\\\u003C 14 days prior to Step 1 registration)\n* STEP 1 - Patient must have received no more than one cycle (28 days or less) of prior chemotherapy and no more than 160 mg of prior dexamethasone (or equivalent dose of prednisone) for treatment of symptomatic myeloma. Patient must not have been exposed to daratumumab for treatment of symptomatic myeloma. Prior radiation therapy to symptomatic lesions is allowed provided there are no residual toxicity related to radiation and blood counts meet the study requirements. Radiation treatment must be completed at least 14 days prior to Step 1 registration\n* STEP 1 - Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of randomization are eligible for this trial\n* STEP 1 - For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated\n* STEP 1 - Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load\n* STEP 1 - Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial\n* STEP 1 - Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better. Patients must not have evidence of current uncontrolled cardiovascular conditions, including hypertension, cardiac arrhythmias, congestive heart failure, unstable angina, or myocardial infarction within 6 months prior to Step 1 registration\n* STEP 1 - Patient may have a history of current or previous deep vein thrombosis (DVT) or pulmonary embolism (PE) but must be willing to take some form of anti-coagulation as prophylaxis if they are not currently on full-dose anticoagulation\n* STEP 1 - Patients with a history of chronic obstructive pulmonary disease (COPD) must have FEV1 testing done within 28 days prior to Step 1 registration and the forced expiratory volume in 1 second (FEV1) must be \\> 50% of predicted normal\n* STEP 2 - Institution must have received Tracking (MRD) test results from Adaptive Biotechnologies\n* STEP 2 - Patient must have completed the Step 1 Induction phase of this protocol without experiencing progression\n* STEP 2 - Patient must be registered to Step 2 within 8 weeks of completing Step 1 Induction Treatment, counting from last day of completion of last cycle\n* STEP 2 - Patient must have an ECOG performance status (PS) of 0-2 (PS 3 allowed if secondary to pain)\n* STEP 2 - Any adverse event(s) related to Step 1 Induction Treatment must have resolved to grade 2 or less\n* STEP 2 - Hemoglobin \\>= 8 g\u002FdL (obtained within 14 days prior to Step 2 randomization)\n* STEP 2 - Platelet count \\>= 50,000\u002Fmm\\^3 (obtained within 14 days prior to Step 2 randomization)\n* STEP 2 - Absolute neutrophil count (ANC) \\>= 1000\u002Fmm\\^3 (obtained within 14 days prior to Step 2 randomization)\n* STEP 2 - Calculated creatinine clearance \\>= 30 mL\u002Fmin (obtained within 14 days prior to Step 2 randomization)\n* STEP 2 - Total bilirubin =\\\u003C 1.5 x ULN (Institutional upper limit of normal) (obtained within 14 days prior to Step 2 randomization)\n* STEP 2 - ALT and AST \\\u003C 3 x ULN (obtained within 14 days prior to Step 2 randomization)\n\nExclusion Criteria:\n\n* STEP 0 - Patient must not have any known allergies, hypersensitivity, or intolerance to corticosteroids, monoclonal antibodies or human proteins, or their excipients (refer to respective package inserts or Investigator's Brochure), or known sensitivity to mammalian-derived products\n* STEP 1 - Women must not be pregnant or breast-feeding due to the potential harm and teratogenic effects to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All females of childbearing potential must have a blood test or urine study with a sensitivity of at least 25 mIU\u002FmL within 10-14 days prior to Step 1 registration to rule out pregnancy and again within 24 hours prior to the first dose of lenalidomide. Females of childbearing potential must also agree to ongoing pregnancy testing while on protocol treatment. A female of childbearing potential is defined as any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria:\n\n  * Has achieved menarche at some point,\n  * Has not undergone a hysterectomy or bilateral oophorectomy; or\n  * Has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)\n* STEP 1 - Women of childbearing potential must not expect to conceive children by using accepted and effective method(s) of contraception (for this protocol defined as the use of TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME for 1) at least 28 days before starting protocol treatment; 2) while participating in the study; 3) during dose interruptions; and 4) for at least 3 months days after the last dose of protocol treatment) OR by practicing true abstinence from sexual intercourse for the duration of their participation in the study (periodic abstinence \\[e.g., calendar, ovulation, symptothermal, post-ovulation methods\\] and withdrawal are not acceptable methods of contraception). Men must not expect to father children by practicing true abstinence from sexual intercourse for the duration of their participation in the study (periodic abstinence \\[e.g., calendar, ovulation, symptothermal, post-ovulation methods\\] and withdrawal are not acceptable methods of contraception) OR use a latex condom during sexual contact with a female of child bearing potential while participating in the study and for at least 3 months after the last dose of protocol treatment even if they have had a successful vasectomy. Men must also agree to abstain from donating sperm while on study treatment and for 3 months after the last dose of protocol treatment even if they have had a successful vasectomy. Both women and men must both agree to abstain from donating blood during study participation and for at least 28 days after the last dose of protocol treatment\n* STEP 1 - Patient must not have peripheral neuropathy \\>= grade 2 on clinical examination or grade 1 with pain at time of Step 1 registration\n* STEP 1 - Patient must not have any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol\n* STEP 1 - Patient must not have moderate or severe persistent asthma within the past 2 years, or uncontrolled asthma of any classification\n\n  * NOTE: Patients who currently have controlled intermittent asthma or controlled mild persistent asthma are allowed to register\n* STEP 1 - Patient must not receive any other concurrent chemotherapy, or any ancillary therapy considered investigational while on this protocol\n\n  * NOTE: Bisphosphonates are considered to be supportive care rather than therapy, and are thus allowed while on protocol treatment\n* STEP 2 - Patient must not have received any non-protocol therapy outside of the assigned Step 1 Induction treatment including stem cell transplant\n* STEP 2 - Women must not be pregnant or breast-feeding due to the potential harm and teratogenic effects to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All females of childbearing potential must have a blood test or urine study with a sensitivity of at least 25 mIU\u002FmL within 10-14 days prior to Step 2 randomization to rule out pregnancy and again within 24 hours prior to the first dose of lenalidomide. Females of childbearing potential must also agree to ongoing pregnancy testing while on protocol treatment. A female of childbearing potential is defined as any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria:\n\n  * Has achieved menarche at some point,\n  * Has not undergone a hysterectomy or bilateral oophorectomy; or\n  * Has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).\n* STEP 2 - Women of childbearing potential must not expect to conceive children by using accepted and effective method(s) of contraception (for this protocol defined as the use of TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME for 1) at least 28 days before starting protocol treatment; 2) while participating in the study; 3) during dose interruptions; and 4) for at least 3 months days after the last dose of protocol treatment) OR by practicing true abstinence from sexual intercourse for the duration of their participation in the study (periodic abstinence \\[e.g., calendar, ovulation, symptothermal, post-ovulation methods\\] and withdrawal are not acceptable methods of contraception).\n\nMen must not expect to father children by practicing true abstinence from sexual intercourse for the duration of their participation in the study (periodic abstinence \\[e.g., calendar, ovulation, symptothermal, post-ovulation methods\\] and withdrawal are not acceptable methods of contraception) OR use a latex condom during sexual contact with a female of child bearing potential while participating in the study and for at least 3 months after the last dose of protocol treatment even if they have had a successful vasectomy. Men must also agree to abstain from donating sperm while on study treatment and for 3 months after the last dose of protocol treatment even if they have had a successful vasectomy. Both women and men must both agree to abstain from donating blood during study participation and for at least 28 days after the last dose of protocol treatment","ALL","18 Years",{"count":19,"type":20},1450,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone.",[26,27,28],"Plasma Cell Myeloma","RISS Stage I Plasma Cell Myeloma","RISS Stage II Plasma Cell Myeloma","RECRUITING","2026-06-16",{"date":32,"type":33},"2026-06-18","ACTUAL",{"date":35,"type":33},"2021-02-24",{"date":37,"type":20},"2027-12-31",{"name":39,"class":40},"ECOG-ACRIN Cancer Research Group","NETWORK",649,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":66},"100507823","phase-1-imaging-study-of-89zrdfo-ys5-for-detecting-cd46-positive-malignancy-in-multiple-myeloma-100507823","NCT05892393","Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma","Pilot PET Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma","Inclusion Criteria:\n\n* Participants must have histologically or cytologically confirmed multiple myeloma by International Myeloma Working Group (IMWG) diagnostic criteria\n* At least one positive myelomatous lesion found on 18F-FDG PET\u002FCT or PET\u002FMRI. A positive lesion is defined as uptake greater than liver on FDG PET, based on the Italian myeloma criteria for PET use (IMPeTUs) criteria\n* Age \\>= 18 years\n* Total bilirubin =\\\u003C 1.5 X institutional upper limit of normal (ULN)\n* Aspartate aminotransferase (AST) =\\\u003C 3 X ULN\n* Alanine aminotransferase (ALT) =\\\u003C 3 X ULN\n* Creatinine clearance \\>= 30 mL\u002Fmin, calculated using the Cockcroft-Gault equation or serum creatinine \\\u003C= 1.5x the institutional upper limit of normal.\n* Ability to understand a written informed consent document, and the willingness to sign it\n\nExclusion Criteria:\n\n* Any condition that, in the opinion of the principal investigator, would impair the participants' ability to comply with study procedures or interfere with the safety of the investigational regimen\n* Individuals who are pregnant or breastfeeding\u002Fchestfeeding.\n* \\- Breast-feeding\u002Fchest-feeding should be discontinued before administration of \\[89ZR\\]DFO-YS5.\n* Females of childbearing potential must have a negative urine or serum pregnancy test (i.e., human chorionic gonadotropin test) within 72 hours prior to administration of \\[89ZR\\]-DFO-YS5.\n* \\- If the urine pregnancy test is positive or equivocal, a confirmatory serum pregnancy test is required. In such cases, the individual must be excluded from participation if the serum pregnancy result is positive.\n* \\- A female is considered to be of childbearing potential (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice), unless it is documented that the individual meets either of the following two criteria: (1) has reached a postmenopausal state ( \\>= 12 continuous months of amenorrhea with no identified cause other than menopause); or (2) has undergone surgical sterilization (i.e., hysterectomy and\u002For bilateral oophorectomy for removal of uterus and\u002For ovaries).\n* Individuals who are pregnant or breastfeeding\u002Fchestfeeding are excluded because there is an unknown but potential risk for adverse effects in the unborn\u002Fnursing child secondary to treatment of the study participant with \\[89ZR\\]-DFO-YS5",{"count":50,"type":20},20,[52],"PHASE1","This phase I trial tests the safety of \\[89Zr\\]DFO-YS5 positron emission tomography (PET) imaging and how well it works to detect CD46 positive cancer cells in patients with multiple myeloma. \\[89Zr\\]DFO-YS5 is an imaging agent called a radiopharmaceutical tracer. A radiopharmaceutical tracer uses a small amount of radioactive material that is injected into a vein to help image different areas of the body. \\[89Zr\\]DFO-YS5 targets a specialized protein called CD46, which is in certain multiple myeloma cancer cells, and \\[89Zr\\]DFO-YS5 PET scans may improve detection of multiple myeloma.",[55,26],"Multiple Myeloma","2026-06-11",{"date":58,"type":33},"2026-06-15",{"date":60,"type":33},"2023-06-16",{"date":62,"type":20},"2026-09-01",{"name":64,"class":65},"Robert Flavell, MD, PhD","OTHER",1,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":21,"phases":76,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":88},"100482388","phase-3-comparing-combinations-of-drugs-to-treat-newly-diagnosed-multiple-myeloma-ndmm-when-a-stem-cell-transplant-is-not-a-medically-suitable-treatment-100482388","NCT05561387","Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment","A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of \"Intermediate Fit\" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance","Inclusion Criteria:\n\n* Participants must have documented multiple myeloma satisfying standard International Myeloma Working Group (IMWG) diagnostic criteria within 28 days prior to registration\n* Participants must have measurable disease within 28 days prior to registration as defined by any of the following:\n\n  * Immunoglobulin (Ig) G myeloma (serum monoclonal paraprotein \\[M-protein\\] level \\>= 0.5 gram\u002Fdeciliter \\[g\u002FdL\\] or urine M-protein level \\>= 200 milligram\\[mg\\]\u002F24 hours\\[hrs\\]); OR\n  * IgA, IgM, IgD, or IgE multiple myeloma (serum M-protein level \\>= 0.2 g\u002FdL or urine M-protein level \\>= 200 mg\u002F24 hrs); OR\n  * Light chain multiple myeloma (serum immunoglobulin free light chain \\>= 10 mg\u002FdL and abnormal serum immunoglobulin kappa lambda free light chain ratio)\n* All disease must be assessed and documented on the baseline\u002Fpre-registration tumor assessment form\n* Participants must have a calculated myeloma frailty index (Myeloma Frailty Score Calculator; http:\u002F\u002Fwww.myelomafrailtyscorecalculator.net\u002F) categorized as frail or intermediate fit (regardless of age) within 28 days prior to registration\n* For Participants Meeting \"Frail\" Status:\n\n  * Participants with any degree of kidney dysfunction are allowed; however, participants on dialysis are not eligible\n* For Participants Meeting \"Frail\" Status:\n\n  * Hemoglobin \\>= 7 g\u002FdL (must be performed within 28 days prior to registration)\n\n    * Note: growth factor and transfusion utilization are allowed if cytopenias are considered secondary to bone marrow involvement from MM)\n* For Participants Meeting \"Frail\" Status:\n\n  * Platelets \\>= 50 x 10\\^9\u002FL (must be performed within 28 days prior to registration)\n\n    * Note: growth factor and transfusion utilization are allowed if cytopenias are considered secondary to bone marrow involvement from MM)\n* For Participants Meeting \"Frail\" Status:\n\n  * Absolute neutrophil count (ANC) \\>= 0.75 x10\\^9\u002FL (must be performed within 28 days prior to registration)\n\n    * Note: growth factor and transfusion utilization are allowed if cytopenias are considered secondary to bone marrow involvement from MM)\n* For Participants Meeting \"Intermediate Fit\" Status, one or more of the following criteria must be present:\n\n  * Kidney dysfunction showing calculated creatinine clearance (CrCl) \\\u003C30 ml\u002Fmin.\n\n    * Actual lab serum creatinine value with a minimum of 0.7 mg\u002FdL.\n  * Participants must have bone marrow function assessed and meet the below criteria ranges:\n\n    * Hemoglobin between 7-8 g\u002FdL, OR\n    * Platelets between 50-75 x10\\^9\u002FL, OR\n    * ANC between 0.75-1 x10\\^9\u002FL\n\n      * Note: growth factor and transfusion utilization are allowed as long as cytopenias are considered secondary to bone marrow involvement from MM)\n  * Revised International Staging System (R-ISS) stage III disease\n  * Note: All labs must be performed within 28 days prior to registration\n* Participants must have a complete medical history and physical exam within 28 days prior to registration\n* Participants must have whole body imaging within 60 days prior to registration. The recommended method of imaging is a positron emission tomography\u002Fcomputed tomography (PET\u002FCT); a low-dose whole body CT scan or whole-body magnetic resonance imaging (MRI) or skeletal survey should be done only if a PET\u002FCT scan cannot be done or is non-feasible. This must be documented in the comments section of the Onstudy form.\n* Total bilirubin =\\\u003C 2 times institutional upper limit of normal (ULN) unless history of Gilbert's disease. Participants with history of Gilbert's disease must have total bilirubin =\\\u003C 5 x institutional ULN (within 28 days prior to registration)\n* Aspartate aminotransferase (AST)\u002Falanine aminotransferase (ALT) =\\\u003C 3 × institutional ULN (within 28 days prior to registration)\n* Participants must have adequate cardiac function, as assessed by the treating physician within 14 days prior to registration. Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, must have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification and must not be assessed as class 3 or 4\n* Participants with known diabetes must show evidence of controlled disease within 14 days prior to registration. Uncontrolled diabetes is defined as: A glycosylated hemoglobin (Hg)A1C \\> 7\n* Participants with known human immunodeficiency virus (HIV)-infection must be receiving anti-retroviral therapy and have an undetectable viral load test on the most recent test result obtained, within 6 months prior to registration\n* All participants with evidence of chronic hepatitis B virus (HBV) infection must have undetectable HBV viral load on suppressive therapy within 28 days prior to registration\n* Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. For participants with HCV infection who are currently on treatment, participant must have an undetectable HCV viral load within 28 days prior to registration\n* Participants must have an Eastern Cooperative Oncology Group (ECOG)\u002FZubrod performance status score of 0-2 (Note: Participants with ECOG\u002FZubrod performance score \\[PS\\] 3, especially where the deterioration of PS is considered secondary to the MM diagnosis, will be allowed)\n* Participants must be offered the opportunity to participate in specimen banking. With participant consent, specimens must be collected and submitted via the Southwest Oncology Group (SWOG) specimen tracking system\n* Participants who are able to complete the patient-reported outcomes measures in English or Spanish must agree to participate in the PRO portion of the study\n* Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines. For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and Central Institutional Review Board (CIRB) regulations\n\nExclusion Criteria:\n\n* Participants must not have received any prior systemic therapy for multiple myeloma with the exception of any one or more of the following:\n\n  * An emergency use of a short course of corticosteroids (equivalent of dexamethasone 160 mg) any time before registration, or\n  * Up to one complete cycle of a non-daratumumab and hyaluronidase-fihj containing anti-myeloma regimen (1 cycle = 21 or 28 days depending on the regimen being used), or\n  * Localized palliative radiation therapy for multiple myeloma, as long as the radiation therapy is completed at least 3 days prior to starting the systemic treatment as per the study protocol.\n* Participants must not have evidence of grade 4 peripheral neuropathy prior to study registration\n* Participants must not have uncontrolled blood pressure within 14 days prior to registration. Uncontrolled blood pressure: systolic blood pressure (SBP) \\> 140 mmHg or diastolic blood pressure (DBP) \\> 90 mmHg. Participants are permitted to be receiving multiple anti-hypertensive medications (unless otherwise indicated in the study). All blood pressure measurements within the 14 days prior to registration must be SBP =\\\u003C 140 and DBP =\\\u003C 90. A participant with a single blood pressure elevation who upon rechecking has a normal blood pressure will remain eligible at the discretion of the registering investigator.\n* Participants must not have a prior or concurrent malignancy whose natural history or treatment (in the opinion of the treating physician) has the potential to interfere with the safety or efficacy assessment of the investigational regimen.\n* Participants must not be pregnant or nursing. Individuals who are of reproductive potential must have agreed to use an effective contraceptive method with details provided as a part of the consent process. A person who has had menses at any time in the preceding 24 consecutive months or who has semen likely to contain sperm is considered to be of \"reproductive potential.\" In addition to routine contraceptive methods, \"effective contraception\" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation\u002Focclusion, and vasectomy with testing showing no sperm in the semen.",{"count":75,"type":20},510,[23],"This phase III trial compares three-drug induction regimens followed by double-or single-drug maintenance therapy for the treatment of newly diagnosed multiple myeloma in patients who are not receiving a stem cell transplant and are considered frail or intermediate-fit based on age, comorbidities, and functional status. Treatment for multiple myeloma includes initial treatment (induction) which is the first treatment a patient receives for cancer followed by ongoing treatment (maintenance) which is given after initial treatment to help keep the cancer from coming back. There are three combinations of four different drugs being studied. Bortezomib is one of the drugs that may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide works by helping bone marrow to produce normal blood cells and killing cancer cells. Anti-inflammatory drugs, such as dexamethasone, lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Daratumumab and hyaluronidase-fihj is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Patients receive 1 of 3 combinations of these drugs for treatment to determine which combination of study drugs works better to shrink and control multiple myeloma.",[26],"2026-06-08",{"date":81,"type":33},"2026-06-10",{"date":83,"type":33},"2023-10-12",{"date":85,"type":20},"2031-05-30",{"name":87,"class":40},"SWOG Cancer Research Network",397,{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":96,"targetDuration":4,"studyType":21,"phases":98,"briefSummary":100,"conditions":101,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":113},"100351619","low-dose-radiotherapy-in-treating-painful-bone-metastases-in-patients-with-multiple-myeloma-100351619","NCT03858205","Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma","Phase II Multi-Institutional Study of Low-Dose (2Gy) Palliative Radiotherapy in the Treatment of Symptomatic Bone Metastases From Multiple Myeloma","Inclusion Criteria:\n\n* Histologic diagnosis of multiple myeloma\n* Painful bone metastasis (index lesion) that has a radiographic correlate\n* Patient may have had any number of prior chemotherapy\u002Fimmunotherapy regimens (changes to systemic therapy or use of bisphosphonates for 4 weeks before and after RT are allowed, but recording of these changes must be made so it can be accounted for)\n* Eastern Cooperative Oncology Group (ECOG) 0-2\n* Brief Pain Inventory (BPI) score \\>= 2\n* Ability to understand and the willingness to sign a written informed consent\n\nExclusion Criteria:\n\n* Patients will be ineligible if the index lesion has received prior radiation therapy or prior palliative surgery. Patients may have received prior palliative or primary radiotherapy or surgery to other parts of the body, as long as the index lesion was not in the prior radiation fields and has not received prior palliative surgery\n* Patients will also be ineligible if there is pathologic fracture or impending fracture at the site of the index lesion or planned surgical fixation of the bone at the index lesion\n* Patients with clinical or radiographic evidence of spinal cord or cauda equina compression\u002Feffacement from the index lesion, and\u002For with index lesions located at the skull base or orbital lesions\n* Patients must not be pregnant",{"count":97,"type":20},100,[99],"NA","This phase II trial studies how well low-dose radiotherapy works in treating bone pain in patients with multiple myeloma that has spread to the bone. Radiation therapy uses high energy x-rays, gamma rays, neutrons, protons, or other sources to kill tumor cells and shrink tumors. Low-dose radiotherapy may be more convenient for patients and their families, may not interfere as much with the timing of chemotherapy, and may have less chance for short term or long-term side effects from the radiation.",[102,103,26],"Bone Pain","Metastatic Malignant Neoplasm in the Bone","2026-06-03",{"date":106,"type":33},"2026-06-05",{"date":108,"type":33},"2019-03-11",{"date":110,"type":20},"2027-03-11",{"name":112,"class":65},"University of Southern California",9,{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":21,"phases":123,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":136},"100378723","early-phase-1-loratadine-for-the-reduction-of-g-csf-induced-bone-pain-in-patients-with-multiple-myeloma-undergoing-stem-cell-mobilization-100378723","NCT04211259","Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization","The Prophylactic Use of Loratadine for Granulocyte-Colony Stimulating Factor (G-CSF) Induced Bone Pain in Multiple Myeloma Patients Undergoing Stem Cell Mobilization","Inclusion Criteria:\n\n* Patient must be able to provide informed consent\n* Patients with confirmed diagnosis of multiple myeloma\n* Able to swallow and retain oral medication\n* All ethnic groups are eligible\n\nExclusion Criteria:\n\n* Non-English speaking person\n* Patients undergoing haploidentical allogeneic hematopoietic stem cell transplant\n* Known allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds\n* Any medical complications or conditions that would, in the investigator's judgement, interfere with full participation in the study\n* On therapeutic dose of aspirin (doses greater than 81 mg) within 7 days prior to the start of the study",{"count":122,"type":20},70,[124],"EARLY_PHASE1","This early phase I trial studies how well loratadine works in reducing granulocyte-colony stimulating factor (G-CSF) induced bone pain in patients with multiple myeloma who are undergoing stem cell mobilization. Loratadine is an antihistamine that may help to reduce or control bone pain during the process of stem cell collection in patients with multiple myeloma.",[26],"2026-05-26",{"date":129,"type":33},"2026-05-29",{"date":131,"type":33},"2022-04-18",{"date":133,"type":20},"2027-06-30",{"name":135,"class":65},"Rutgers, The State University of New Jersey",2,{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":144,"phases":4,"briefSummary":145,"conditions":146,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":66},"100440111","neurocognitive-outcomes-after-whole-brain-radiation-therapy-for-hematologic-malignancies-100440111","NCT05011045","Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies","Inclusion Criteria:\n\n* Age 18 years or older\n* Treatment with radiation therapy to the brain for a hematologic malignancy (ex. primary central nervous system lymphoma \\[PCNSL\\], secondary central nervous system lymphoma \\[SCNSL\\], leukemia, myeloma)\n* Proficient and capable of completing tests in English\n* Patients with claustrophobia are eligible if the claustrophobia is managed with medication\n* Patients with cognitively-impairment are eligible if the impairment is managed with medication\n* Patients who are pregnant",{"count":97,"type":20},"OBSERVATIONAL","This study assesses neurocognitive outcomes after receiving radiation therapy to the brain (whole brain radiation therapy) in patients with blood cancers (hematologic malignancies). This may help researchers learn more about the effects of whole brain radiation therapy on memory and thinking in patients with blood cancer.",[147,148,149,150,26,151],"Central Nervous System Lymphoma","Hematopoietic and Lymphoid Cell Neoplasm","Leukemia","Lymphoma","Secondary Central Nervous System Lymphoma","2026-05-18",{"date":154,"type":33},"2026-05-20",{"date":156,"type":33},"2020-01-09",{"date":158,"type":20},"2026-10-31",{"name":160,"class":65},"M.D. Anderson Cancer Center",{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":21,"phases":170,"briefSummary":171,"conditions":172,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":66},"100463250","non-chemotherapeutic-interventions-for-the-improvement-of-quality-of-life-and-immune-function-in-patients-with-multiple-myeloma-100463250","NCT05312255","Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma","Improving Host Factors in Patients With Monoclonal Gammopathies and Other Hematologic Disorders","Inclusion Criteria:\n\n* Age \\>= 18 years of age\n* Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of:\n\n  * Module A: ECOG 0 - 1\n  * Module B: ECOG 0 - 2\n  * Module C: ECOG 0 - 2\n  * Module D: ECOG 0-1\n* MODULE A, B and C: Have a diagnosis of smoldering multiple myeloma, multiple myeloma or plasma cell leukemia (PCL) or\n* MODULE D: non transfusion dependent low-risk MDS\n* Show no signs of comorbidities, myeloma symptoms, or treatment side effects that would put them in danger when participating in the study according to the physician's discretion\n* Are able to understand and follow assessment and intervention procedures\n* Participant must understand the investigational nature of this study and sign an Independent Ethics Committee\u002FInstitutional Review Board approved written informed consent form prior to receiving any study related procedure\n* MODULE A and D (PHYSICAL ACTIVITY): Participant has access to a personal computer or tablet with camera, microphone, speakers and internet access\n* MODULE B (NUTRITION): Not applicable\n* MODULE C (BETA BLOCKER): Newly diagnosed patients with multiple myeloma necessitating treatment and before initiation of systemic therapy\n* MODULE C: Female participants of child-bearing potential must have a negative pregnancy test at study entry and then agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry. Male patients with female partners of child-bearing potential should also use adequate contraceptive methods (see above). Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately MODULE D: Patients with MDS not necessitating transfusion therapy at time of enrollment (no transfusion within 8 weeks prior to enrollment) i.e. patients on observation, or receiving growth factors or luspatercept only\n\nExclusion Criteria:\n\n* Major comorbidities that would cause danger to the patient when participating in the study and that would have a risk of progression if the patient took part in the study (including, but not limited to): cardiac or pulmonary and infectious diseases (e.g., ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia) or, psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Unwilling or unable to follow protocol requirements\n* Any condition which in the investigator's opinion deems the participant an unsuitable candidate to take part in study intervention (comorbidities, myeloma symptoms, treatment side effects)\n* MODULE A (PHYSICAL ACTIVITY): Current and symptomatic pathological fracture(s) or severely advanced instability of the musculo-skeletal system that is deemed to making the patient unsafe to participate. This will be assessed by radiologist, a neurosurgeon and\u002For an orthopedic surgeon, if applicable.\n* MODULE A (PHYSICAL ACTIVITY): Current and symptomatic pathological fracture(s) or severely advanced instability of the musculo-skeletal system\n* MODULE A (PHYSICAL ACTIVITY): Acute bone instability as assessed by whole body low-dose computed tomography and evaluated by an experienced surgeon\n* MODULE B (NUTRITION): Clinical signs of malnutrition (body mass index \\[BMI\\] \\\u003C 18)\n* MODULE B (NUTRITION): Special diets (physician prescribed)\n* MODULE B (NUTRITION): Diabetic treated with glucose-lowering medications and\u002For insulin\n* MODULE B (NUTRITION): Other reasons not to withhold food\n* MODULE B (NUTRITION): Any condition which in the investigator's opinion deems the participant an unsuitable candidate to limit food consumption\n* MODULE C (BETA BLOCKER): Current use of a beta blocker (includes all non-selective and beta-1 selective blockers) or, use of a beta-blocker within 3 months of study enrollment\n* MODULE C (BETA BLOCKER): Contraindications to the use of beta-blockers, e.g.; severe sinus bradycardia; sick sinus syndrome; or heart block greater than first-degree, uncontrolled depression, unstable angina pectoris, uncontrolled heart failure (New York Heart Association \\[NYHA\\] Grade III or IV), hypotension ( systolic blood pressure \\\u003C 100 mmHg), severe asthma or chronic obstructive pulmonary disease (COPD), uncontrolled type I or type II diabetes mellitus (HbA1C \\> 8.5 or 12h fasting plasma glucose \\> 160 mg\u002FdL at screening), symptomatic peripheral arterial disease or Raynaud's syndrome, untreated pheochromocytoma, current calcium channel blocker use (Non-dihydropyridines such as verapamil) or rhythm control agents such as digoxin and amiodarone. Patients with pacemakers will be excluded\n* MODULE C (BETA BLOCKER): Pregnant or nursing female participants, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test\n* MODULE D: Cardiovascular disease which is deemed limiting exercise readiness by a cardiologist",{"count":169,"type":20},175,[99],"This clinical trial investigates the effect of non-chemotherapeutic interventions in patients with multiple myeloma or MDS. Non-chemotherapeutic interventions such as physical activity and nutritional interventions (e.g., modifications in diet) have been shown to positively affect the immune system and improve overall quality of life. Another purpose of this study is for researchers to learn how the addition of a beta-blocker (propranolol) to the standard treatment regimen in patients with newly diagnosed multiple myeloma affects immune response and quality of life. A study from the Mayo Clinic looked at multiple myeloma patients who were on a beta-blocker while undergoing chemotherapy and found that the use of a beta-blocker resulted in improved patient survival outcomes. Non-chemotherapeutic treatment options may help decrease symptoms and improve quality of life for patients with multiple myeloma.",[26,173,174,175],"Recurrent Plasma Cell Myeloma","Refractory Plasma Cell Myeloma","Smoldering Plasma Cell Myeloma","2025-11-28",{"date":178,"type":33},"2025-12-01",{"date":180,"type":33},"2022-06-28",{"date":182,"type":20},"2027-06-28",{"name":184,"class":65},"Roswell Park Cancer Institute",{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":4,"eligibilityCriteria":191,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":192,"targetDuration":4,"studyType":21,"phases":194,"briefSummary":196,"conditions":197,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":66},"100455266","phase-2-belantamab-mafodotin-pomalidomide-and-dexamethasone-for-the-treatment-of-high-risk-myeloma-100455266","NCT05208307","Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma","Maintenance Therapy With Belantamab, Pomalidomide and Dexamethasone (BPd) in High-Risk Myeloma Patients: A Phase 2 Study With a Safety Run-In","Inclusion Criteria:\n\n* Transplant-eligible myeloma patient that has undergone autologous stem cell transplant (ASCT) within one year of their diagnosis and has achieved \\>= partial response (PR) based on IMWG standard criteria. Patients will be enrolled within day 60-100 after ASCT\n* Patient's with high-risk disease defined as\n\n  * Presence of del(17p); t(4;14); t(14;16); t(14;20) by fluorescence in situ hybridization (FISH) or by cytogenetics (CTG)\n  * Plasma cell leukemia at diagnosis with \\>= 20% circulating plasma cells on peripheral blood\n* Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status of =\\\u003C 2\n* Participant must be \\>= 18 years of age\n* Absolute neutrophil count (ANC) \\>=1.5 x 10\\^9\u002FL (performed within 28 days of initiation of protocol therapy unless otherwise specified)\n* Hemoglobin \\>= 8.0 g\u002FdL (performed within 28 days of initiation of protocol therapy unless otherwise specified)\n* Platelets \\>= 75 x 10\\^9\u002FL (performed within 28 days of initiation of protocol therapy unless otherwise specified)\n* Total bilirubin =\\\u003C 1.5 x upper limit of normal (ULN) (Isolated bilirubin \\>= 1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin \\\u003C 35%) (performed within 28 days of initiation of protocol therapy unless otherwise specified)\n* Alanine aminotransferase (ALT) =\\\u003C 2.5 x ULN (performed within 28 days of initiation of protocol therapy unless otherwise specified)\n* Estimated glomerular filtration rate (eGFR) \\>= 30 mL\u002Fmin\u002F 1.73 m\\^2 (performed within 28 days of initiation of protocol therapy unless otherwise specified)\n* Spot urine (albumin\u002Fcreatinine ratios) \\\u003C 500 mg\u002Fg (56 mg\u002Fmmol) (performed within 28 days of initiation of protocol therapy unless otherwise specified)\n* Female participants: contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:\n\n  * Is not a woman of childbearing potential (WOCBP) OR\n  * Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of \\\u003C 1% per year), preferably with low user dependency, during the intervention period and for at least 4 months after the last dose of study intervention and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention.\n\nWOCBP refers to sexually mature female, regardless of sexual orientation or whether they have undergone tubal ligation, who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally menopausal for at least 24 consecutive months. A WOCBP must have a negative highly sensitive serum pregnancy test (as required by local regulations) within 72 hours before the first dose of study intervention. The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with a nearly undetected pregnancy.\n\nNonchildbearing potential is defined as follows (by other than medical reasons):\n\n* \\>= 45 years of age and has not had menses for \\> 1 year\n* Patients who have been amenorrhoeic for \\\u003C 2 years without history of a hysterectomy and oophorectomy must have a follicle stimulating hormone value in the postmenopausal range upon screening evaluation\n* Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound. Tubal ligation must be confirmed with medical records of the actual procedure\n\n  * Male participants: contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Male participants are eligible to participate if they agree to the following during the intervention period and for 6 months after the last dose of study treatment to allow for clearance of any altered sperm:\n* Refrain from donating sperm PLUS either:\n* Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent OR\n* Must agree to use contraception\u002Fbarrier as detailed below:\n\n  * Agree to use a male condom, even if they have undergone a successful vasectomy, and female partner to use an additional highly effective contraceptive method with a failure rate of \\\u003C 1% per year as when having sexual intercourse with a woman of childbearing potential (including pregnant females)\n\n    * All prior treatment-related toxicities (defined by National Cancer Institute- Common Toxicity Criteria for Adverse Events \\[NCI-CTCAE\\], version 4.03) must be =\\\u003C grade 1 at the time of enrolment except for alopecia\n    * Participant must be able to understand the study procedures and agree to participate in the study by providing written informed consent\n\nExclusion Criteria:\n\n* Participant must not have current corneal epithelial disease except mild changes in corneal epithelium\n* Participant must not have current unstable liver or biliary disease defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis\n\n  * Note: Stable non-cirrhotic chronic liver disease (including Gilbert's syndrome or asymptomatic gallstones) or hepatobiliary involvement of malignancy is acceptable if otherwise meets entry criteria\n* Participant must not have presence of active renal condition (infection, requirement for dialysis or any other condition that could affect participant's safety). Participants with isolated proteinuria resulting from multiple myeloma (MM) are eligible, provided they fulfil inclusion criteria\n* Participant must not use contact lenses while participating in this study\n* Participant must not be simultaneously enrolled in any interventional clinical trial\n* Participant must not have used an investigational drug or approved systemic anti-myeloma therapy (including systemic steroids) within 14 days or five half-lives, whichever is shorter, preceding the first dose of study drug\n* Participant must not have had plasmapheresis within 7 days prior to first dose of study treatment\n* Participant must not have received prior treatment with a monoclonal antibody within 30 days of receiving the first dose of study drugs\n* Participant must not have had major surgery =\\\u003C 4 weeks prior to initiating study treatment\n* Participant must not have any evidence of active mucosal or internal bleeding\n* Participant must not have evidence of cardiovascular risk including any of the following:\n\n  * Evidence of current clinically significant uncontrolled arrhythmias, including clinically significant electrocardiogram (ECG) abnormalities such as 2nd degree (Mobitz Type II) or 3rd degree atrioventricular (AV) block\n  * History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting within three (3) months of Screening\n  * Class III or IV heart failure as defined by the New York Heart Association functional classification system (NYHA, 1994)\n  * Uncontrolled hypertension\n* Participant must not have known immediate or delayed hypersensitivity reaction or idiosyncratic reactions to belantamab mafodotin or drugs chemically related to belantamab mafodotin, or any of the components of the study treatment\n* Participant must not have an active infection requiring treatment\n* Known human immunodeficiency virus (HIV) infection, unless the participant can meet all of the following criteria:\n\n  * Established anti-retroviral therapy (ART) for at least 4 weeks and HIV viral load \\\u003C 400 copies\u002FmL\n  * CD4+ T-cell (CD4+) counts \\>= 350 cells\u002FuL\n  * No history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections within the last 12 months\n  * Note: consideration must be given to antiretroviral therapy (ART) and prophylactic antimicrobials that may have a drug:drug interaction and\u002For overlapping toxicities with belantamab mafodotin or other combination products as relevant\n* Positive hepatitis C antibody test result or positive hepatitis C ribonucleic acid (RNA) test result at screening or within 3 months prior to first dose of study treatment unless the participant can meet the following criteria:\n\n  * RNA test negative\n  * Successful anti-viral treatment (usually 8 weeks duration) is required, followed by a negative hepatitis C virus (HCV) RNA test after a washout period of at least 4 weeks\n* Patients will hepatitis B will be excluded unless the following criteria can be met\n\n  * SEROLOGY: Hepatitis B core antibody positive (HbcAb+), hepatitis B surface antigen negative (HbsAg-); SCREENING: Hepatitis B virus (HBV) deoxyribonucleic acid (DNA) undetectable; DURING STUDY TREATMENT: Monitoring per protocol, antiviral treatment instituted if HBV DNA becomes detectable\n  * SEROLOGY: HBsAg+ at screen or within 3 months prior to first dose; SCREENING: HBV DNA undetectable, highly effective antiviral treatment started at least 4 weeks prior to first dose of study treatment, baseline imaging per protocol, participants with cirrhosis are excluded; DURING STUDY TREATMENT: Antiviral treatment maintained throughout study treatment, monitoring and management per protocol\n\n    * Note: presence of hep B surface antibody (HBsAb) indicating previous vaccination will not exclude a participant\n* Participant must not have invasive malignancies other than disease under study, unless the second malignancy has been medically stable for at least 2 years and, in the opinion of the principal investigators, will not affect the evaluation of the effects of clinical trial treatments on the currently targeted malignancy. Participants with curatively treated non-melanoma skin cancer may be enrolled without a 2-year restriction\n* Participant must not have any serious and\u002For unstable pre-existing medical, psychiatric disorder, or other conditions (including lab abnormalities) that could interfere with participant's safety, obtaining informed consent or compliance to the study procedures\n* Diagnosed with smoldering MM, monoclonal gammopathy of undetermined significance, Waldenstrom's macroglobulinemia, polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome, amyloidosis or standard risk myeloma or secondary plasma cell leukemia\n* High risk patients that did not achieve \\>= PR after stem cell transplant\n* Participant has \\>= grade 2 peripheral neuropathy on clinical examination within 28 days before initiation of protocol therapy\n* Participants must not be pregnant or lactating\n* Any condition, including laboratory abnormalities, that in the opinion of the investigator places the subject at unacceptable risk if he\u002Fshe were to participate in the study\n* Prior malignancy (within the last 5 years) except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer\n* Known hypersensitivity to acyclovir or similar anti-viral drug\n* Known intolerance to steroid therapy\n* Contraindication or prior intolerance to thromboembolic prophylaxis with aspirin, warfarin or low-molecular weight heparin\n* Participants with known central nervous system (CNS) disease\n* Poor tolerability or known allergy to any of the study drugs or compounds of similar chemical or biologic composition to dexamethasone, boron or mannitol",{"count":193,"type":20},34,[195],"PHASE2","This phase II trial studies the effect of belantamab mafodotin, pomalidomide, and dexamethasone in treating patents with high-risk myeloma. Belantamab mafodotin is a monoclonal antibody, called belantamab, linked to a chemotherapy drug, called mafodotin. Belantamab is a form of targeted therapy because it attaches to specific molecules on the surface of cancer cells, known as BCMA receptors, and delivers mafodotin to kill them. Chemotherapy drugs, such as pomalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Giving belantamab mafodotin, pomalidomide, and dexamethasone may kill more cancer cells.",[26],"2025-08-25",{"date":200,"type":33},"2025-09-02",{"date":202,"type":33},"2022-07-21",{"date":204,"type":20},"2027-10-21",{"name":206,"class":65},"Emory University"]